Overview

Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC

Status:
Not yet recruiting

Trial end date:
2024-06-30

Target enrollment:

Participant gender:

Summary

Focusing on the current status of clinical treatment of MVI-positive postoperative liver cancer, single-center clinical trial studies have verified the safety and effectiveness of TACE combined with lenvatinib in preventing postoperative recurrence of MVI-positive HCC patients. Explore a new clinical first-line treatment plan for patients with liver cancer microvascular invasion after surgery.

Phase:

Phase 4

Details

Lead Sponsor:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Treatments:

Lenvatinib